Trial · NCT02089802
Optimizing Pazopanib Exposure in RCC Patients
NCT02089802, Phase 2, Terminated, Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimizing Pazopanib Exposure in RCC Patients. Trials, record NCT02089802. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02089802
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimizing Pazopanib Exposure in RCC Patients
- NCT number
- NCT02089802
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
- Conditions
- Locally Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Interventions
- Pazopanib
- First posted
- 2014-03-18
- Last updated
- 2017-08-18
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determine if in patients with a Pazopanib plasma trough level of ≤ 20 μg/mL a plasma trough level of > 20 ≤g/mL can be achieved by dose escalation. | 14 days after each dose optimization. | |
| Secondary | Comparison of tumor response of patients with normal and low Pazopanib plasma trough levels. | Up to 28 days after last dose. | Comparison of patients with normal Pazopanib plasma trough levels ("normal plasma level patients; NPLP) with patients with low Pazopanib plasma trough levels ("Low plasma level patients"; LPLP) with regard to the therapeutic result. |
| Secondary | Objective remission rate. | Up to 28 days after last dose. | |
| Secondary | Progression free survival. | Up to 28 days after last dose. | |
| Secondary | Overall survival. | Up to 28 days after last dose. | |
| Secondary | Comparison of LPLP in whom the plasma trough level could be optimized successfully and LPLP in whom the plasma trough level could not be optimized with regard to above parameters. | Up to 28 days after last dose. | |
| Secondary | Correlation of plasma trough levels and side effects, especially high blood pressure. | Up to 28 days after last dose. | |
| Secondary | Correlation of the occurrence of high blood pressure with oncological result (response rate). | Up to 28 days after last dose. | |
| Secondary | Recording of demographic data, compliance, concomitant medication, and correlation with plasma trough levels (LPLP / NPLP). | Up to 28 days after last dose. | |
| Secondary | Examination of life quality. | Up to 28 days after last dose. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02089802
GET https://conductscience.org/api/trials/v1/NCT02089802/registered